Haseki Tıp Bülteni (Jan 2023)
Comparison of the Diagnostic Accuracy of the Gamma-Glutamyl Transpeptidase to Platelet Ratio and Systemic Inflammation Response Index in Non-Alcoholic Fatty Liver Disease
Abstract
Aim:The aim of this study was to evaluate the diagnostic usability of the systemic inflammation response index (SIRI) and the gamma-glutamyl transpeptidase to platelet ratio (GPR) in non-alcoholic fatty liver (NAFL).Methods:This is a case-control study that was conducted with patients who came to a hospital for a check-up between July 2020 and July 2021, in the internal medicine outpatient clinic of a tertiary care university hospital. The existence and severity of NAFL were confirmed with ultrasonography, and patients were divided into two groups, mild and advanced, according to the severity of NAFL. Body mass index (BMI), alanine aminotranspherase (ALT), aspartate aminotranspherase (AST), gamma-glutamyl transpeptidase (GGT), complete blood count parameters, and erythrocyte sedimentation rates (ESR) were compared between groups.Results:In total, 665 patients were enrolled in the study, and in 347 (52.3%) of them, the existence of NAFL was confirmed. Of the patients who had NAFL, 184 had mild (grade1), whereas 163 had advanced (grade 2 and 3) steatosis. The differences were significant in age and gender distribution, BMI, ESR, ALT, AST values, GPR, AST to platelet ratio (APRI), and fibrosis-4 (FIB-4) scores between the NAFL and control groups. Univariate regression analyses revealed an increased risk for the development of NAFL in BMI, ALT, AST, ESR, GPR, APRI, and FIB-4 variables. Age, BMI, GPR, and ALT were found to be independent risk factors for the development of NAFL in multivariate analyses. Gamma-glutamyl transpeptidase to platelet ratio was found to be the most effective parameter for predicting the existence of NAFL.Conclusion:The gamma-glutamyl transpeptidase to platelet ratio is a new and simple marker for predicting the existence of NAFL.
Keywords
